Hematology and Blood Disorders

Hematologic Toxicities and Side Effects of Cancer Therapy

The Hematologic Toxicities and Side Effects of Cancer Therapy track at the 21st Global Summit on Hematology and Blood Disorders (Blood Disorder 2025) will focus on the critical issue of hematologic complications arising from cancer treatments. Researchers are encouraged to submit abstracts that explore the incidence, mechanisms, and management of blood-related toxicities and side effects associated with chemotherapy, targeted therapies, and immunotherapies. This track will present cutting-edge research on the pathophysiology of treatment-induced hematologic disorders, including cytopenias, thrombocytopenia, and anemia, as well as strategies for mitigating these adverse effects.

Attendees can expect detailed presentations from leading experts, case studies on clinical management, and discussions on innovative approaches to prevent and treat hematologic toxicities. Interactive sessions will facilitate dialogue on integrating new findings into clinical practice and improving patient outcomes. Additionally, the track will provide valuable networking opportunities, enabling participants to connect with specialists in oncology and hematology, exchange insights, and explore collaborative solutions. This track aims to advance understanding of the impact of cancer therapies on blood health and promote effective strategies to manage and reduce hematologic side effects.